2002/01/18

Your Amazon.com Order is almost complete

In case you cannot see images

Amazon
Account View Your Balance Past Orders(1) Wish List(2)
Your Account > Manage Your Account > Product Details

Reveal Your Order Shipping Status Arcojedi.ignoble

Reference : RE892339762-MAY-30
Amazon Customer: arcojedi.ignoble@blogger.com
Product Name: Home Energy Saver Device.
Product Desc: Power your home, office, appliances, etc at a drastically reduced monthly cost.
Your code for single or multiple item can be accessed for purchases today.
 
Confirm your Order
 
Have a wonderful Day - Amazon

Through extensive analysis and research this theatre and its host building, the carpenter centre I believe that this truly is a remarkable form, an excellent piece of design. The theatre works with and answers to every one of its parametric challenges. Through the use of parametric design I feel that a form has been created that would otherwise never have been imagined or realised. The organic form of the theatre, created using very non organic production techniques answers to the brief on so many levels. It creates this new heart, new hub for the Carpenter Centre. It does not try and mimic the great modernist architecture used by Corbusier himself, but in no regard does it fight against it, it somehow moves in to an architecture beyond, with each individual member of the theatre being very geometric, but arranged in an intelligent way, produce a form which is more organic. Neither structures the same but they do work together. The puppet theatre design speaks of the Carpenter centre today; it speaks not of the architecture and the Carpenter Centre of the past, but the architecture, the people and the Carpenter Centre of the future. The architects could have chosen so many different approaches to producing a pavilion of sort on this site but I'm positive they would have struggled to produce a design that overall worked more responsively with the entirety of the design challenge presented. The second example of parametric architecture that I have analysed is the Mercedes Benz Museum, Un Studio, Stuttgart 2005 - with parametric and algorithmic working by Designtoproduction. This example of parametric design was selected not for its obviously parametric appearance but for the way in which parametric modelling combined with BIM was used in the construction and design of what can only be seen as a truly revolutionary building. Today the majority of the worlds exceptional historical, cultural and artistic pieces of are all in place, the future of the museum, as seen with this, the Mercedes Benz museum, lies with those who can fully communicate a specialist collection, what they are about and where they came from. They have the capability to stimulate a culture much more than a generalist collection, the works, the cars in the museum coud be seen to speak much more of the people that the majority of today's art. This is where the use of parametric design can be seen to influence and completely communicate the work of Mercedes in a new way. The importance of museum design has been at the forefront of architectural thinking since Frank Lloyd Wright first challenged the plan of the museum with the design of the Solomon R. Guggenheim Museum in New York, 1969. Since then museum has been challenged again and again by a multitude of architects such as Renzo Piano & Richard Rodgers with The Pompidou Centre, Paris, 1977 and Daniel Libeskind with the Jewish Museum, Berlin, opened 2001. The Mercedes Benz Museum can be seen to relate to all of these examples in its pursuit to step forward away from the regular, to challenge the spaces, circulation paths and forms of a museum, to create a museum of purpose. The success of a museum depends upon the inventiveness of its internal arrangement, spaces created and its ability to exhibit artefacts within these spaces in a relevant way. The museum will / has become famous not only in the continuing line of challenging museum architecture starting with buildings such as Frank Lloyd Wright's Guggenheim in New York but for putting the digital design process firmly on the map. Stuttgart is home of the Mercedes Benz brand, and so with the need of a new museum, UN studios were chosen to redesign a new museum on a new site close to the main gateway to the city, where the old museum had previously been located in a dedicated building within the actual Mercedes factory. The design is based on a concept involving the over laying of three circular forms in plan with the removal of the central space creating a triangular shaped building height atrium area. In section the building raises over eight floors in a double helix form, maximising space and providing 16,500 square meters of useable space on a relatively small footprint. Originally the brief brought to UN studio suggested that the building should be no more than two storeys high with worries that any more height in the building may cause complications with exhibits, for example the manoeuvring and exhibiting of lorries, circulation problems around such large pieces and structural integrity of the building with extremely heavy exhibit loads. With the site being situated so close to a major motorway it was soon suggested by UN studios that the building should be taller relating to the close situation to the motorway, seeing that problems such as circulation and weight of exhibits could be overcome with the correct knowledge and attitude towards the project. The circulation system used in the Mercedes Benz Museum s similar to that used in the pompidou centre Paris, with the circulation running around the external facade of the building. In a similar way, the circulation can be seen to draw clear links with the ramp like circulation of the Guggenheim New York. The main difference with both of these buildings is that the Mercedes Benz museum has, through advanced construction techniques combined with the use of parametric modelling is able to convey the main forces applied to the building to a structural core through floor slabs rather than perimeter, therefore fully liberating the facade and plan of the building.

Nom more emails 108 Washington st Newell Wv 26050-1120

2002/01/17

You have never seen this before

arcojedi.ignoble@blogger.com

Women - Want to Drop 10-Ibs and Keep it Off For Good Easily?

This Tip Is Not For Men
New research shows exactly WHY it is so much harder for women than it is for men to lose and keep off weight. This exciting tips really works.

You can expect to drop 3 dress sizes in only ONE week.

This unusual tip strategically allows you to eat what you'd like while losing dress sizes in the meanwhile.

You've never seen anything like this before.

Limited Availability
Go Here to Find Out Exactly What This Trick Is:








http://mailstore1.diteavens.com/17240096557/42386=4618790270 1904 N Midland dr Apt 32 Midland TX 79707-6434




AstraZeneca and Eli Lilly and Company (Lilly) have revealed about their collaboration for clinical trials to evaluate the safety and preliminary efficacy of AstraZeneca�s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA�), Lilly�s VEGF Receptor 2 antiangiogenic cancer medicine. The planned study will assess the combination as a treatment for patients with advanced solid tumours. The Phase I study is expected to establish the safety and a recommended dosing regimen, with the potential to open expansion cohorts in various tumours of interest, for the combination of MEDI4736 and ramucirumab. Under the terms of the agreement, the trial will be sponsored by Lilly. Additional details of the collaboration, including tumour types to be studied and financial terms, were not disclosed. MEDI4736 is a monoclonal antibody developed by MedImmune, AstraZeneca�s global biologics research and development arm, directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. Ramucirumab is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that specifically binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. Preclinical data indicate that combining VEGFR inhibitors with immune checkpoint blockades, such as PD-L1 targeted agents, has the potential to enhance anti-tumour activity. Robert Iannone, Head of Immuno-oncology, Global Medicines Development at AstraZeneca, said: �We believe that combination therapy in immuno-oncology has the potential to transform the way cancer is treated. MEDI4736 is supported by a comprehensive development programme and is emerging as a cornerstone of our combination-focused immuno-oncology pipeline targeting multiple tumour types. Our collaboration with Lilly is a great addition to our programme and provides the opportunity to explore another exciting, novel combination that could deliver important clinical benefit to cancer patients.� �The development of immune checkpoint inhibitors has been one of the more exciting research advancements in recent oncology history, but it is going to be even more interesting to see how these inhibitors can be combined with other proven targeted therapies,� said Richard Gaynor, M.D., senior vice president, product development and medical affairs, Lilly Oncology. �This collaboration represents the next wave of immuno-oncology research by bringing together two innovative medicines � Lilly�s CYRAMZA and AstraZeneca�s MEDI4736 � as a novel combination that we hope will one day provide new cancer treatment solutions.�
 
 

 

2002/01/16

Stop Paying Mechanics, Use this trick

FINAL WARRANTY NOTICE - TIME SENSITIVE MATERIAL
Notification that your factory warranty might be expiring or has currently expired! Confirm your extended protection Today
*** This is our final time trying to inform you ***
Never pay for an auto repair bill again Click Here
Hello Arcojedi.ignoble,

Fact: Auto repair bills are expensive. (Never pay for a covered auto repair bill again. )
Customer ID No:
Registered Owner
Status:
Arcojedi.ignoble
Confirmation Needed
Offer Deadline Date:
Pre-Approval Code
Vehicle Year/Make
CONFIDENTIAL
Confirm your extended protection today Click Here

 

 

 

 

 

 

 

This email is an advert isement to extend your coverage. Remove me from list 9 Gibson Dr Hazlet NJ 07730-2620

If you would no longer like to receive these from us, click here

A recent fossil find is more evidence that the well-known �Lucy� species was not alone in the region now known as Ethiopia, a new study suggests. A lower jaw, along with jaw fragments and teeth, dated at between 3.3 million to 3.5 million years old, were found in the Afar region of northern Ethiopia four years ago. The discovery shows that a second human ancestor lived in about the same area and time frame a Lucy�s species, researchers said. However, not everyone agrees with that notion. The journal Nature released a paper Wednesday announcing the new find and assigned it to a species they dubbed Australopithecus deyiremeda. In the Afar language the second name means �close relative,� referring to its apparent relationship to later members of the evolutionary tree. Yohannes Haile-Selassie of the Cleveland Museum of Natural History, who led the discovery team, says nobody knows just how it�s related to our own branch of the family tree. Previously, fossilized foot bones found in 2009 near the new discovery site had indicated the presence of a second species. But those bones were not assigned to any species, and it is still unclear whether they belong to the newly identified species, Haile-Selassie said. If they don't, that would indicate yet another species from the same time and region as Lucy's species, Australopithecus afarensis. Bernard Wood of George Washington University said the discovery provides �compelling evidence� that a second creature lived in the vicinity of Lucy�s species at the same time. Wood wonders how they shared the landscape. "These fossils certainly create an agenda for a lot of interesting research that's going to be done in the next decade," Wood said. As evidence that the new fossils represent a previously unknown species, the researchers cite specific anatomical differences with known fossils. But Tim White, a University of California, Berkeley, expert in human evolution, was unimpressed.

2002/01/15

Drinking this (at breakfast) will shred 5.2 kg of pure fat

Mayo
Clinic
Daily F at Loss Tips
Add This To Your Breakfast, Lose Wei ght!

This easy-to-make shake is currently helping thousands of people with obesity.

People who tried this recipe over 1 week lost an average of 5.5kgs!

I was pronounced dead by the doctors beacuase of my weight. This recipe saved my life!
Mike - Severe Obese Patient
this shake increases fat burning rate by 200 percent

Get the Recipe Here - The clock hits zero tonight

 

 

 

 

We understand, let us know if you want to be removed http://mx1c2.broncbuoys.com/36767416485118546707188880 3004 Summit ave Fl 1 Baltimore MD 21234-1887

Patients who used cells from this STD to treat their melanoma were 8 times more likely to survive than a control group A genetically modified strain of herpes can kill cancer cells and stop tumors from growing, according to new research. The strain, called T-Vec, was used to treat patients with melanoma as part of one of the final phases of testing of a new drug. The research, published in the Journal of Clinical Oncology, is the latest to show how viruses may be used clinically to kill cancer cells. Unlike chemotherapy, which casts a wide net and kills any proliferating cells, viruses often narrowly target cancer cells, which could make them more effective in fighting the disease. The method also appeals to researchers because it activates the immune system to fight cancer.

Researchers looked at more than 400 patients with aggressive malignant melanoma, the deadliest type of skin cancer. More than 16% of patients given the T-Vec treatment showed a lasting response for six months, compared with 2% of members of the control group given normal treatment. �We may normally think of viruses as the enemies of mankind, but it�s their very ability to specifically infect and kill human cells that can make them such promising cancer treatments,� said professor Paul Workman, chief executive of the Institute of Cancer Research, in a statement. The drug, produced by Amgen, now awaits approval from the U.S. Food and Drug Administration before it will be offered to patients.

Label Cloud

Technology (1097) News (595) Military (498) Microsoft (492) Business (487) Developer (382) Music (351) Software (318) Audio (316) Government (308) Security (300) Love (262) Books (257) Apple (236) Dungeons and Dragons (228) Funny (209) Google (194) Yahoo (186) Mobile (179) Storage (178) Adobe (176) Wishlist (159) Astrology (137) Local (137) Art (134) Investing (125) Shopping (124) AMD (105) Hardware (105) Neatorama (94) Blogger (93) Education (72) Movies (61) Mozilla (61) Dictionary (59) Weather (48) Video Games (44) Television (36) VoIP (25) meta (23) Holidays (14) Entertainment (12) Christian (11)